Hormone therapy initiation after the Women's Health Initiative
Authors:
- Katherine M. NewtonKNKatherine M. Newton
- Diana S.M. BuistDBDiana S.M. Buist
- Onchee YuOYOnchee Yu
- Cynthia L. HartsfieldCHCynthia L. Hartsfield
- Susan E. AndradeSASusan E. Andrade
- Feifei WeiFWFeifei Wei
- Maureen T. ConnellyMCMaureen T. Connelly
- K. Arnold ChanKCK. Arnold Chan
- 1 May 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Menopause
- Vol. 15 (3) , 487-493
Abstract
OBJECTIVES: To describe hormone therapy (HT) initiation after the 2002 publication of the Women\u27s Health Initiative. DESIGN: Observational cohort (1999-2003) of women ages 40 to 79 years, five health plans, used HT in July 2002 and subsequently discontinued or never used before August 2002. RESULTS: Of discontinuers, 15.8% (3,203 of 20,205) reinitiated HT. Reinitiation was higher among estrogen users (23.8%) versus estrogen with progestin users (11.3%), and lower among those with diabetes (relative risk [RR]=0.68, 95% CI: 0.61-0.76), cardiovascular disease (RR=0.87, 95% CI: 0.83-0.92), and hyperlipidemia (RR=0.83, 95% CI: 0.79-0.88). Only 2.3% (2,072 of 90,261) of never users initiated (August 2002 to December 2003). First-time initiation was associated with cardiovascular disease (RR=1.17, 95% CI: 1.10-1.25) and hyperlipidemia (RR=1.24, 95% CI: 1.17-1.33) and was less common among those with diabetes (RR=0.70, 95% CI: 0.63-0.79). CONCLUSIONS: After the Women\u27s Health Initiative, a minority of women reinitiated or became first-time initiators of HT. Women with cardiovascular disease, diabetes, and hyperlipidemia were less likely to reinitiate; women with cardiovascular disease and hyperlipidemia were more likely to be first-time initiatorsKeywords
This publication has 16 references indexed in Scilit:
- Health System Responses to the Women's Health Initiative Findings on Estrogen and Progestin: Organizational ResponseJNCI Monographs, 2005
- Symptom Experience After Discontinuing Use of Estrogen Plus ProgestinJAMA, 2005
- Hormone use and patient concerns after the findings of the Women's Health InitiativeMenopause, 2005
- The impact of comorbidities on hormone useJournal of General Internal Medicine, 2005
- Hormone Therapy Prescribing Patterns in the United StatesObstetrics & Gynecology, 2004
- Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause SocietyMenopause, 2004
- Promotion and Prescribing of Hormone Therapy After Report of Harm by the Women’s Health InitiativeJAMA, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on therapeuticsPharmacoepidemiology and Drug Safety, 2001
- A Chronic Disease Score with Empirically Derived WeightsMedical Care, 1995